Rule of three

Less than two months into 2013, Avalon Ventures has completed a hat trick of exits. The third score was last week's partnership between portfolio company RQx Pharmaceuticals Inc. and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) to discover and develop compounds against an undisclosed target.